XML 43 R31.htm IDEA: XBRL DOCUMENT v3.19.1
Collaborative Agreements (Details) - USD ($)
 1 Months Ended 12 Months Ended
May 06, 2016
Dec. 29, 2015
Dec. 24, 2018
Sep. 30, 2017
Sep. 25, 2017
Jul. 24, 2017
May 26, 2017
Feb. 28, 2017
Mar. 31, 2016
Dec. 31, 2018
Dec. 31, 2017
Collaborative Agreements (Textual)                      
Common stock newly issued, value                   $ 80,000 $ 5,850,000
Outstanding balance                   2,550,000
Collaborative Arrangement [Member]                      
Collaborative Agreements (Textual)                      
Description of payment settlement   Upfront payment shall upon the signing of this BioLite Collaborative Agreement: 3.5% of total payment. After receiving upfront payment from BriVision, BioLite has to deliver all data to BriVision in one week. Upon the first IND submission, BriVision shall pay, but no later than December 15, 2016: 6.5% of total payment. After receiving second payment from BriVision, BioLite has to deliver IND package to BriVision in one week. At the completion of first phase II clinical trial, BriVision shall pay, but no later than September 15, 2017: 15% of total payment. After receiving third payment from BriVision, BioLite has to deliver phase II clinical study report to BriVision in three months. Upon the phase III IND submission, BriVision shall pay, but no later than December 15, 2018: 20% of total payment. After receiving forth payment from BriVision, BioLite has to deliver IND package to BriVision in one week. At the completion of phase III, BriVision shall pay, but no later than September 15, 2019:25% of total payment. After receiving fifth payment from BriVision, BioLite has to deliver phase III clinical study report to BriVision in three months. Upon the NDA submission, BriVision shall pay, but no later than December 15, 2020, BriVision shall pay: 30% of total payment. After receiving sixth payment from BriVision, BioLite has to deliver NDA package to BriVision in one week.                  
Amount received from BriVision   $ 100,000,000       $ 3,000,000          
Upfront payments   $ 3,500,000                  
Percentage of payments under collaborative agreement   3.50%       50.00%       15.00%  
Milestone payments to BioLite in cash $ 2,600,000                    
Common stock newly issued, value $ 900,000         $ 3,000,000          
Common stock newly issued, shares 562,500                    
Share price $ 1.60             $ 2.0      
Licensing rights                   $ 10,000,000  
Accounts payable                   $ 15,000,000  
Agreement, terms   This BioLite Collaborative Agreement shall, once signed by both Parties, remain in effect for fifteen years as of the first commercial sales of the Product in the Territory and automatically renew for five more years unless either party gives the other party six month written notice of termination prior to the expiration date of the term.                  
Collaborative Arrangement One [Member]                      
Collaborative Agreements (Textual)                      
Percentage of payments under collaborative agreement                 6.50%    
Milestone payments to BioLite in cash               $ 650,000      
Common stock newly issued, value               $ 5,850,000      
Common stock newly issued, shares               2,925,000      
Share price               $ 2.0      
Licensing rights         $ 3,000,000            
Accounts payable                 $ 6,500,000    
Research and development expense                     3,000,000
Co-Dev Agreement [Member]                      
Collaborative Agreements (Textual)                      
Amount received from BriVision             $ 3,000,000       $ 450,000
Percentage of payments under collaborative agreement             50.00%        
Company cash payments       $ 3,000,000     $ 3,000,000        
Co-Dev agreement, description     the Company received the remaining balance of $2,550,000 in the form of newly issued shares of Rgene's Common Stock, at the price of NT$50 (approximately equivalent to $1.60 per share), for an aggregate number of 1,530,000 shares, which accounted for equity method long-term investment as of December 31, 2018. During the year ended December 31, 2018, the Company has recognized investment loss of $549.